Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 169 clinical trials
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  • 1950 views
  • 25 Mar, 2021
  • 107 locations
featured
GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

  • 270 views
  • 08 Nov, 2020
  • 1 location
featured
Ovarian, Fallopian Tube or Peritoneal Cancer

Ovarian, Fallopian Tube or Peritoneal Cancer

  • 621 views
  • 08 Nov, 2020
  • 1 location
featured
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

  • 524 views
  • 08 Nov, 2020
  • 1 location
featured
featured
Advanced Ovarian Cancer

Advanced Ovarian Cancer

  • 116 views
  • 08 Nov, 2020
  • 1 location
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

  • 84 views
  • 19 Sep, 2021
  • 294 locations
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

ovarian, fallopian tube or primary peritoneal cancer. - The tolerability of the combination at the MTD of EGEN-001 assessed in combination with PLD. - The

intraperitoneal chemotherapy
doxorubicin
peritoneal cancer
doxil
  • 227 views
  • 08 Nov, 2020
  • 1 location
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

niraparib dual therapy in patients with platinum-resistant recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (ovarian cancer).

  • 0 views
  • 27 Jan, 2021
  • 1 location